

Clinical Trial Opportunities and Resources

As a service to OA members, we bring to you several oncology clinical trial resources, including online matching services, hotlines and clinical trial participation opportunities. Please find this valuable information below.

Amgen

www.amgentrials.com

AmgenTrials.com is dedicated to bringing education and awareness of Amgen's clinical trials to patient and healthcare communities.

MGI PHARMA, INC.

CURRENT TRIAL Protocol IROF-018

THREE-ARM RANDOMIZED PHASE II

CLINICAL STUDY: Of Irofulven/Prednisone, Irofulven/Capecitabine/Prednisone or Mitoxantrone/Prednisone in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer Patients

TRIAL DESCRIPTION: Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven-based regimens compared to mitoxantrone + prednisone in patients with hormone-refractory prostate cancer (HRPC) whose disease has progressed following Taxotere[®] based regimens. Upon determination of eligibility, patients will randomly be assigned to receive one of three treatment arms: 1) irofulven + prednisone; 2) irofulven + capecitabine + prednisone; or

3) mitoxantrone + prednisone. For every five patients randomized, two will receive treatment #1 (irofulven + prednisone), 2 patients will receive treatment #2 (irofulven + capecitabine + prednisone), and one patient will receive treatment #3 (mitoxantrone + prednisone). This is not a blinded study, so both the patient and doctor will know which treatment has been assigned.

MGI Medical Communications phone number: 800-562-5580.

Novartis eTRIALS

www.novartisclinicaltrials.com/etrials/home.do

Hotline: 800-340-6843

Find the information you need to make educated decisions about participating in a Novartis clinical trial. Whether you are a patient or a caregiver, Novartis' goal is to answer your questions and help you understand the trial experience.

CURRENT TRIAL: Non-small Cell Lung Cancer Study US75 (Z-PACT). This study will evaluate the effects of an investigational drug in combination with chemotherapy in patients with stage IIIB/IV non-small cell lung

cancer. This study is for lung cancer patients that cannot be treated by surgery. This treatment is being studied to see if it can improve the response to cancer treatment and if it is an effective treatment to delay the progression of lung cancer to areas within the bones.

TRIAL PHASE: Phase 2

PARTICIPATION DURATION: Up To 12 months
Visit www.novartisclinicaltrials.com/etrials/home.do to register for this trial. There is a high-level screening process required to participate in this study.

sanofi aventis

www.aventisoncology.com/clinical_start.htm

CLINICAL TRIAL MATCHING & REFERRAL

SERVICE: The Clinical Trial Matching & Referral Service, powered by emergingmed.com, is designed to provide a fast, simple, and confidential way to obtain information about cancer clinical trials sponsored or supported by Aventis Pharmaceuticals. This service is free.

Questions? Call toll free 1-800-Rx-Trial or send an email to: contactus@88rxtrial.com.

Patient Assistance

The following programs are provided as a service to your patients for product access and assistance. Qualified patients can range from those with no insurance to the underinsured, or those who have difficulty meeting a co-pay. Eligibility and enrollment for each program varies, so please visit the appropriate website or call the contact numbers listed below to learn more about individual guidelines.

Amgen

The SAFETY NET[®] Program

800-272-9376

www.amgen.com/patient/assistance.html

GlaxoSmithKline

Commitment to Access

866-265-6491

www.commitmenttoaccess.gsk.com

MedImmune

Ethylol Protect Program

877-633-4411

MGI PHARMA, INC.

ALOXI Alliance Program

866-302-5694

www.YESCTRL.com

The YES to CONTROL Patient Program

866-937-2875

www.YESCTRL.com

Novartis Oncology

Novartis Patient Assistance Program

866-4-ZOMETA and 877-LAR-HELP

(866-496-6382 and 877-527-4357)

Ortho Biotech

PROCritline

800-553-3851

(available Mon.-Fri. from 9am-8pm, EST)

Fax: 800-987-5572

www.Procritline.com

(site offers online application and registration)

Pharmion

The VIDAZA Patient Assistance Program

866-742-7646 www.vidaza.com

Innohep Patient Assistance Program

www.innohepusa.com

Roche, Inc.

Oncoline-Patient Assistance Program

800-443-6676

(press 2 to be connected directly to a representative)

www.kytril.com

sanofi aventis

PACT+ Program

800-996-ONCO (6626)

www.aventisoncology.com/reimbursement.htm

ePACT@access2health.com

SICOR

SICOR Patient Assistance Program

800-331-0124

Wyeth

Wyeth Oncology Reimbursement Program

888-638-6342